

## Medincell to Present Data Showing Enhanced Potential of Tumor-Targeting Monoclonal Antibody in Melanoma Using BEPO® Technology

Medincell will provide an overview of some of its R&D programs related to its cutting-edge Long-Acting Injectable technologies through several presentations and posters at the CRS 2024 conference, from July 8 to 12 in Bologna, Italy, including:

- **Oncology field:** Presentation of in vivo data showing the improved immunomodulatory potential of a tumor-targeting monoclonal antibody in melanoma using BEPO® technology for peritumoral administration.
- **Introduction to BEPO® STAR:** Overview of the novel Medincell's proprietary Long-Acting Injectable technology designed to enhance controlled delivery across a broader range of drugs and therapeutic areas.
- **Medincell proprietary in vitro release tool:** Presentation of an innovative in vitro lab tool designed to accelerate formulation activities and preclinical candidates selection.

**Adolfo Lopez-Noriega, Head of R&D at Medincell, said:** *"Innovation is our cornerstone, driving our advanced technologies and their groundbreaking applications. Our world-class R&D team is dedicated to continuously pushing the boundaries, enhancing our technology's reach, and ensuring our position at the forefront of controlled and targeted drug delivery. Our advancements aim to deliver superior therapeutic options through systemic or local delivery in areas where we can make a significant impact, such as psychiatry, oncology, obesity, or pain management. Attending CRS allows us to share our recent achievements and underscores our commitment to forging strong partnerships with both academia and pharmaceutical companies."*

Organized by the Controlled Release Society, the CRS Annual Meeting is a prominent conference in the field of controlled release science and technology. It covers a wide range of topics, including drug delivery systems, biomaterials, nanotechnology, polymers, and regulatory aspects of controlled release products. It's a major event for all academics and pharmaceutical industry professionals involved in the development and application of controlled release technologies.

Event website: <https://2024crsannualmeeting.eventscribe.net/>

### About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.

UZEDY® and SteadyTeq™ are registered trademarks of Teva Pharmaceuticals.

**[www.medincell.com](http://www.medincell.com)**

### Contact

**David Heuzé - Head of Corporate and Financial Communications, and ESG**  
david.heuze@medincell.com / +33 (0)6 83 25 21 86

**Grace Kim - Head of US Financial Strategy and IR**  
grace.kim@medincell.com / +1 (646) 991-4023

**Investors Relations France**  
**Louis-Victor Delouvrier/Alban Dufumier**  
medincell@newcap.eu / +33 (0)1 44 71 94 94

**Media Relations**  
**Nicolas Mérigeau**  
medincell@newcap.eu / +33 (0)1 44 71 94 94

This press release may contain forward-looking statements, particularly concerning the progress of the Company's clinical trials. Although the Company considers that its forecasts are based on reasonable assumptions, any statements other than statements of historical fact that may be contained in this press release relating to future events are subject to change without notice, to factors beyond the Company's control and to the Company's financial capabilities.

These statements may include, but are not limited to, any statements beginning with, followed by or including words or expressions such as "objective", "believe", "expect", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "should", "could" and other words or expressions of similar meaning or used in the negative. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control which may cause actual results, performance or achievements of the Company to differ materially from those anticipated or implied by such statements.

A list and description of such risks, hazards and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (AMF) pursuant to its regulatory obligations, including in the Company's document de base, registered with the AMF on September 4, 2018 under number I. 18-062, as well as in documents and reports to be published subsequently by the Company. Furthermore, these forward-looking statements only apply as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update these forward-looking statements, nor to update the reasons why actual results may differ materially from those anticipated in the forward-looking statements, even if new information becomes available. The Company's updating of one or more forward-looking statements does not imply that it will or will not update these or any other forward-looking statements.

This press release is published for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of the Company in any jurisdiction whatsoever, particularly in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not intended to address the investment objectives, financial situation or specific needs of any particular recipient. It should not be relied upon as a substitute for the exercise of your own judgement. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be restricted by law in certain jurisdictions. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions.